文献速递骨软组织肉瘤与黑色素瘤

晚期罕见皮肤癌抗PD-1治疗潜力分析

Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas.
PubMed 文献 · Eur J Cancer · 2025-04-04

本综述聚焦皮肤附属器癌、乳腺外Paget病、皮肤血管肉瘤和Kaposi肉瘤,汇总其局部复发率、转移率、肿瘤突变负荷、PD-L1表达及超适应症使用全身抗PD-1药物的文献数据,发现部分患者即使缺乏PD-L1表达或TMB较低仍可见缓解,但所用药物种类繁多、患者数相对较少,限制了个体疗效解读。

要点

  • 皮肤附属器癌、皮肤血管肉瘤和Kaposi肉瘤的PD-L1表达与TMB高度可变。
  • 部分肿瘤缺乏PD-L1表达或TMB较低时仍可见抗PD-1治疗缓解。
  • 文献报告的晚期罕见皮肤癌抗PD-1最佳总体缓解令人鼓舞,多在其他全身治疗失败后。

核心结论

  • 文献中晚期罕见皮肤癌患者接受抗PD-1药物治疗的最佳总体缓解令人鼓舞,但所用药物种类多、患者数相对较少,限制了对个体疗效的解读。

研究设计与样本

  • 本综述聚焦皮肤附属器癌、乳腺外Paget病、皮肤血管肉瘤和Kaposi肉瘤,汇总其局部复发率、转移率、TMB、PD-L1表达及超适应症全身抗PD-1药物治疗情况。

主要发现

  • 皮肤附属器癌(取决于组织学亚型)、皮肤血管肉瘤和Kaposi肉瘤的PD-L1表达与TMB高度可变,部分缺乏PD-L1表达或TMB较低的肿瘤仍可见缓解。
  • 皮脂腺癌3例(完全缓解2例、部分缓解1例),汗孔癌5例(完全缓解3例、部分缓解1例、疾病进展1例),螺旋腺癌2例(部分缓解1例、疾病进展1例),毛根鞘癌1例部分缓解。
  • 乳腺外Paget病9例(完全缓解1例、部分缓解5例、疾病进展3例),皮肤血管肉瘤32例(完全缓解5例、部分缓解18例、疾病进展9例),Kaposi肉瘤92例(完全缓解5例、部分缓解53例、疾病稳定23例、疾病进展11例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所用抗PD-1药物种类繁多,单药或联合其他全身治疗,患者数相对较少,限制了对个体疗效的解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review, focusing on cutaneous adnexal carcinomas, extramammary Paget disease (EMPD), cutaneous angiosarcomas (cAS) and Kaposi sarcoma (KS), summarizes their local recurrence and metastasis rates, tumor mutation burden (TMB), PD-L1 expression, and off-label treatment with systemic anti-PD-1 agents. PD-L1 expression and tumor mutation burden (TMB) were highly variable in adnexal carcinomas (also depending on the histological subtype), cAS and KS tumors, and some responses were noted even in lack of PD-L1 expression or in low-TMB tumors. There were encouraging best overall responses in patients with advanced rare skin carcinomas treated with anti-PD-1 agents in the literature, mostly after failure of other systemic treatments. We identified a total of 3 patients with sebaceous carcinoma (2 with complete response [CR], 1 with partial response [PR]), 5 with porocarcinoma (3 CR, 1 PR, 1 progression of disease [PD]), 2 with spiradenocarcinoma (1 PR, 1 PD), 1 with trichilemmal carcinoma with PR, 9 with EMPD (1 CR, 5 PR, 3 PD), 32 with cAS (5 CR, 18 PR, 9 PD), and 92 with KS (5 CR, 53 PR, 23 SD, 11 PD). However, a large variety of anti-PD-1 agents were used, in monotherapy or in combination with other systemic therapy, in a relatively small number of patients, limiting interpretations on their individual efficacy. The development of clinical guidelines on rare skin carcinomas may provide standardized guidance to physicians towards best care.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dessinioti C, Stratigos AJ. Mapping the potential for anti-PD-1 therapy in advanced rare skin carcinomas. Eur J Cancer. 2025. PMID: 40294476. doi:10.1016/j.ejca.2025.115403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。